Santen Ventures co-led a series B round also backed by C-Mer Eye Care and BioLight Life Science to bring Belkin Laser's funding total to $16.3m.

The gene therapy developer has followed a $120m round co-led by Novo three weeks ago by filing to go public on the Nasdaq Global Select Market.

Fidelity led a series C round for haematology and cancer therapy developer Antengene, whose corporate shareholders include Celgene, Taikang, Tigermed and WuXi AppTec.

Novo-backed immuno-oncology drug developer Checkmate Pharmaceuticals has filed to go public a month after its last funding round.

The Nikon and Varian-backed cell biology technology developer floated in a $178m offering and its shares almost tripled in price on their first day of trading.

GlaxoSmithKline is paying $176m for a 10% stake in the RNA drug developer in connection with a strategic partnership agreement.

The Roche and GSK-backed autoimmune disease drug developer has gone public in an upsized initial public offering after at least $138m in earlier funding.

Alphabet and EmblemHealth returned to help supply $53.5m for the community-focused care provider, bringing its overall funding to nearly $140m.

Adimab's coronavirus antibody spinoff has launched with series A financing from investors including GV as it prepares for its first clinical trials.

Existing investor Bioventus has returned to reinvest in the bone implant provider, whose existing backers include Johnson & Johnson Innovation – JJDC.